Navigation Links
Boston Scientific Welcomes House Passage of National Pain Care Policy Act
Date:3/31/2009

NATICK, Mass., March 31 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed passage of the National Pain Care Policy Act of 2009 by the U.S. House of Representatives. The legislation, which was introduced by Rep. Lois Capps (D-California) and Rep. Mike Rogers (R-Michigan), will help evaluate the current state of chronic pain care in the United States.

A companion to the House bill was introduced in the U.S. Senate by Senators Orrin Hatch (R-Utah) and Chris Dodd (D-Connecticut) on March 19.

Both bills expand research by the Pain Consortium at the National Institutes of Health on the causes and potential treatments for pain, provide greater education and training for health care professionals, create a national pain management public awareness campaign, and call on the Institute of Medicine to convene a conference on pain care.

"These bills are important to pain patients and the health care professionals who serve them," said Ramsin Benyamin, MD, DABIPP, Clinical Assistant Professor of Surgery, College of Medicine, University of Illinois. "As a pain physician, I applaud Congress for advancing the understanding of chronic pain and its debilitating effect on millions of patients."

"We are very pleased that the House of Representatives passed the National Pain Care Policy Act, acknowledging the importance of proper pain care," said Michael Onuscheck, President of Boston Scientific's Neuromodulation business. "As a leader in this industry, Boston Scientific believes it is critical to improve care for pain patients. We hope that the swift passage by the House will send a strong message to the Senate of the importance of passing this legislation, and we will continue to work to achieve that goal for the millions suffering from chronic pain."

Chronic pain affects an estimated 75 million Americans and presents a major challenge for the U.S. health care system.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

About Boston Scientific Neuromodulation

Boston Scientific Neuromodulation is an innovation leader in implantable pain management technology. The use of pulses of electricity delivered directly to the nerves, known as Spinal Cord Stimulation, has been in use for more than 30 years without the unwanted side effects and long-term costs associated with pain medications. Spinal Cord Stimulation is a reversible therapy that has helped thousands of people find relief from chronic pain.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, regulatory approval of our products, our growth strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:  Paul Donovan
              508-650-8541 (office)
              508-667-5165 (mobile)
              Media Relations
              Boston Scientific Corporation

              Larry Neumann
              508-650-8696 (office)
              Investor Relations
              Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
2. Boston University School of Medicine researcher recipient of Memory Ride Grant
3. Success of Shape-Up Somerville Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston
4. AAHFNs 2008 Annual Meeting in Boston Will Be Raising the Bar in Heart Failure Care
5. Families Invited to Celebrate Shire Day at Boston Childrens Museum
6. Boston Scientific Announces New Initiatives to Increase Shareholder Value
7. Boston Scientific Announces Additions to Clinical Sciences Organization
8. Boston University School of Medicine physician receives award from AATOD
9. Boston Scientific Announces Verdict in Cordis Litigation
10. Boston Scientific Announces Sale of Cardiac Surgery and Vascular Surgery Businesses
11. Boston Scientific and GE Healthcare Announce their First Patient Data Link to Electronic Medical Record
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their ... that they have achieved certification to ISO 13485. This certification is another way they ... to date products and services that they need. , The ISO 13485 Certification is ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Hear the ... project with the donation of cochlear implants. In February 2017, the first three ... a fair chance of leading an independent life. This engagement builds on the ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... January is National Stalking Awareness Month ... choose to lurk in the corners and commit the crime of stalking, a very real ... and addiction, an often overlooked factor in stalking and other crimes. , “Stalking: know it. ...
(Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
(Date:1/17/2017)... ... January 17, 2017 , ... Kevin Harrington (one of the original Sharks from ... campaigns regarding the topic of Beauty and Personal Care. , Everyone ... better way to commit to these changes than beginning with personal care and beauty ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... SAN DIEGO , Jan. 18, 2017 /PRNewswire/ ... manufacturing solutions for cell and advanced therapies , ... the French biopharmaceutical company developing "tumor starvation" treatments ... unmet medical needs. Under the agreement, Invetech will ... products based on Erytech,s proprietary ERYCAPS technology platform, ...
(Date:1/18/2017)... January 18, 2017 After the recent ... the use of cannabis both for medical and recreational purposes ... Americans open to the use of cannabis, but the focus ... to Arcview Market Research, the North American legal cannabis market ... the previous year. The research projects sales will grow at ...
(Date:1/17/2017)... 2017 North America Insulin Delivery Market Outlook ... America Insulin Delivery Market Outlook to 2022", provides key ... The report provides value, in millions of US dollars, ... segments - Insulin Pens, Insulin Pumps, Insulin Syringes and ... company shares and distribution shares data for each of ...
Breaking Medicine Technology: